Epidemiology, ventilation management and outcomes of COVID-19 ARDS patients versus patients with ARDS due to pneumonia in the Pre-COVID era

Respir Res. 2024 Aug 17;25(1):312. doi: 10.1186/s12931-024-02910-2.

Abstract

Background: Ventilation management may differ between COVID-19 ARDS (COVID-ARDS) patients and patients with pre-COVID ARDS (CLASSIC-ARDS); it is uncertain whether associations of ventilation management with outcomes for CLASSIC-ARDS also exist in COVID-ARDS.

Methods: Individual patient data analysis of COVID-ARDS and CLASSIC-ARDS patients in six observational studies of ventilation, four in the COVID-19 pandemic and two pre-pandemic. Descriptive statistics were used to compare epidemiology and ventilation characteristics. The primary endpoint were key ventilation parameters; other outcomes included mortality and ventilator-free days and alive (VFD-60) at day 60.

Results: This analysis included 6702 COVID-ARDS patients and 1415 CLASSIC-ARDS patients. COVID-ARDS patients received lower median VT (6.6 [6.0 to 7.4] vs 7.3 [6.4 to 8.5] ml/kg PBW; p < 0.001) and higher median PEEP (12.0 [10.0 to 14.0] vs 8.0 [6.0 to 10.0] cm H2O; p < 0.001), at lower median ΔP (13.0 [10.0 to 15.0] vs 16.0 [IQR 12.0 to 20.0] cm H2O; p < 0.001) and higher median Crs (33.5 [26.6 to 42.1] vs 28.1 [21.6 to 38.4] mL/cm H2O; p < 0.001). Following multivariable adjustment, higher ΔP had an independent association with higher 60-day mortality and less VFD-60 in both groups. Higher PEEP had an association with less VFD-60, but only in COVID-ARDS patients.

Conclusions: Our findings show important differences in key ventilation parameters and associations thereof with outcomes between COVID-ARDS and CLASSIC-ARDS.

Trial registration: Clinicaltrials.gov (identifier NCT05650957), December 14, 2022.

Keywords: ARDS; Acute respiratory distress syndrome; COVID–19; Critical care; Mechanical ventilation; Ventilation management.

Publication types

  • Observational Study

MeSH terms

  • Adult
  • Aged
  • COVID-19* / mortality
  • COVID-19* / therapy
  • Female
  • Humans
  • Male
  • Middle Aged
  • Pneumonia* / complications
  • Respiration, Artificial*
  • Respiratory Distress Syndrome* / mortality
  • Respiratory Distress Syndrome* / therapy
  • Treatment Outcome

Associated data

  • ClinicalTrials.gov/NCT05650957